Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
The initiative was announced at World Hypertension Congress, Chennai
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Scores highest PAT of Rs. 118 crore in FY25
This marks yet another milestone in our series of successful audits over the past year
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Findings likely to generate hypotheses about potential new uses of drugs
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
AstraZeneca Pharma India discontinues manufacturing of Imdur
Subscribe To Our Newsletter & Stay Updated
